Haemophilus influenzae Type B Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Haemophilus influenzae Type B Infections – Pipeline Review, H2 2016’, provides an overview of the Haemophilus influenzae Type B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections

The report reviews pipeline therapeutics for Haemophilus influenzae Type B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Haemophilus influenzae Type B Infections therapeutics and enlists all their major and minor projects

The report assesses Haemophilus influenzae Type B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

Biological E. Limited

Daiichi Sankyo Company, Limited

Indian Immunologicals Limited

Kaketsuken K.K.

LG Life Science LTD.

Panacea Biotec Limited

Sanofi Pasteur SA

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Haemophilus influenzae Type B Infections Overview 8

Therapeutics Development 9

Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9

Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10

Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11

Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 12

Haemophilus influenzae Type B Infections - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Haemophilus influenzae Type B Infections - Products under Development by Companies 16

Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 18

Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 19

Beijing Minhai Biotechnology Co., Ltd 19

Biological E. Limited 20

Daiichi Sankyo Company, Limited 21

Indian Immunologicals Limited 22

Kaketsuken K.K. 23

LG Life Science LTD. 24

Panacea Biotec Limited 25

Sanofi Pasteur SA 26

Sinovac Biotech Ltd. 27

Zydus Cadila Healthcare Limited 28

Haemophilus influenzae Type B Infections - Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

(meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Eupenta - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

haemophilus influenzae B vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Haemophilus influenzae B vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Haemophilus influenzae B vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

hemophilus influenza [serotype B] vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

KD-370 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

LT-Hib - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

NU-300 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VN-0105 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Haemophilus influenzae Type B Infections - Dormant Projects 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2016 9

Number of Products under Development for Haemophilus influenzae Type B Infections – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Products under Investigation by Universities/Institutes, H2 2016 18

Haemophilus influenzae Type B Infections – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 19

Haemophilus influenzae Type B Infections – Pipeline by Biological E. Limited, H2 2016 20

Haemophilus influenzae Type B Infections – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 21

Haemophilus influenzae Type B Infections – Pipeline by Indian Immunologicals Limited, H2 2016 22

Haemophilus influenzae Type B Infections – Pipeline by Kaketsuken K.K., H2 2016 23

Haemophilus influenzae Type B Infections – Pipeline by LG Life Science LTD., H2 2016 24

Haemophilus influenzae Type B Infections – Pipeline by Panacea Biotec Limited, H2 2016 25

Haemophilus influenzae Type B Infections – Pipeline by Sanofi Pasteur SA, H2 2016 26

Haemophilus influenzae Type B Infections – Pipeline by Sinovac Biotech Ltd., H2 2016 27

Haemophilus influenzae Type B Infections – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 28

Assessment by Monotherapy Products, H2 2016 29

Assessment by Combination Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Haemophilus influenzae Type B Infections – Dormant Projects, H2 2016 59

Haemophilus influenzae Type B Infections – Dormant Projects (Contd..1), H2 2016 60

List of Figures

List of Figures

Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2016 9

Number of Products under Development for Haemophilus influenzae Type B Infections – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 29

Assessment by Combination Products, H2 2016 30

Number of Products by Targets, H2 2016 31

Number of Products by Stage and Targets, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports